30 Technology
  • Home
  • About Us
    • Overview
    • Partnerships
    • Leadership Team
    • Scientific Advisory Board
  • Business Areas
    • 30 Respiratory
    • 30 Therapeutics
    • 30 Animal Health
    • Pipeline
  • Nitric Oxide
  • News & Events
    • News
    • Media Coverage
  • Careers
  • Contact
Select Page

Sitemap

Authors

  • 30 Technology
  • Brett Worth

Pages

  • About us
  • Business Areas
  • Careers
  • Contact
  • Cookies
  • Data Protection
  • Home
  • Media Coverage
  • News & Events
  • Our Nitric Oxide Technology
  • Privacy Notice
  • History
  • Partnerships
  • Scientific advisory board

Sitemap

  • News

    • 30 Technology expands its clinical team
    • 30 Technology receives regulatory approval for TASK tuberculosis Study in South Africa
    • 30 Technology Expands Its Scientific Team And Opens New Innovation Hub At Scale Space, Imperial College London
    • 30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis
    • 30 Technology launches a critical clinical trial of RESP301 in cystic fibrosis patients with serious lung infections
    • Thirty Respiratory receives approval for multicentre post-exposure clinical trial of RESP301 to prevent transmission of COVID-19 in the community
    • 30 Technology announces first patients enrolled in UK clinical trial (NOCoV2) for the treatment of COVID-19
  • Press Releases

    • 30 Technology’s Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications

30 TECHNOLOGY Therapeutic Nitric Oxide

REGISTERED OFFICE

Thirty Holdings Limited
1 Red Place
London W1K 6PL
United Kingdom

Links

Privacy notice
Cookies
Data protection
Sitemap

Legal

Registered in England
No.11614943
© 30 Technology 2023
All Rights Reserved

Contact

contact@30.technology
+44 (0) 1235 431 201

  • Follow